-
3
-
-
60749083864
-
Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis
-
E.W. Orenstein, S. Basu, N.S. Shah, J.R. Andrews, G.H. Friedland, A.P. Moll, and et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis Lancet Infect Dis 9 2009 153 161
-
(2009)
Lancet Infect Dis
, vol.9
, pp. 153-161
-
-
Orenstein, E.W.1
Basu, S.2
Shah, N.S.3
Andrews, J.R.4
Friedland, G.H.5
Moll, A.P.6
-
5
-
-
77951864345
-
Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections
-
P. Jureen, K. Angeby, E. Sturegard, E. Chryssanthou, C.G. Giske, J. Werngren, and et al. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections J Clin Microbiol 48 2010 1853 1858
-
(2010)
J Clin Microbiol
, vol.48
, pp. 1853-1858
-
-
Jureen, P.1
Angeby, K.2
Sturegard, E.3
Chryssanthou, E.4
Giske, C.G.5
Werngren, J.6
-
6
-
-
0029018979
-
A suggested approach to once-daily aminoglycoside dosing
-
E.J. Begg, M.L. Barclay, and S.B. Duffull A suggested approach to once-daily aminoglycoside dosing Br J Clin Pharmacol 39 1995 605 609
-
(1995)
Br J Clin Pharmacol
, vol.39
, pp. 605-609
-
-
Begg, E.J.1
Barclay, M.L.2
Duffull, S.B.3
-
7
-
-
0034861424
-
Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis
-
M. Zhu, W.J. Burman, G.S. Jaresko, S.E. Berning, R.W. Jelliffe, and C.A. Peloquin Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis Pharmacotherapy 21 2001 1037 1045
-
(2001)
Pharmacotherapy
, vol.21
, pp. 1037-1045
-
-
Zhu, M.1
Burman, W.J.2
Jaresko, G.S.3
Berning, S.E.4
Jelliffe, R.W.5
Peloquin, C.A.6
-
8
-
-
2942536119
-
Aminoglycoside toxicity: Daily versus thrice-weekly dosing for treatment of mycobacterial diseases
-
C.A. Peloquin, S.E. Berning, A.T. Nitta, P.M. Simone, M. Goble, G.A. Huitt, and et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases Clin Infect Dis 38 2004 1538 1544
-
(2004)
Clin Infect Dis
, vol.38
, pp. 1538-1544
-
-
Peloquin, C.A.1
Berning, S.E.2
Nitta, A.T.3
Simone, P.M.4
Goble, M.5
Huitt, G.A.6
-
9
-
-
0036636358
-
Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis
-
P. de Jager, and R. van Altena Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis Int J Tuberc Lung Dis 6 2002 622 627
-
(2002)
Int J Tuberc Lung Dis
, vol.6
, pp. 622-627
-
-
De Jager, P.1
Van Altena, R.2
-
10
-
-
67649143314
-
Prevention and modulation of aminoglycoside ototoxicity
-
Review
-
G. Perletti, A. Vral, M.C. Patrosso, E. Marras, I. Ceriani, P. Willems, and et al. Prevention and modulation of aminoglycoside ototoxicity Mol Med Rep 1 2008 3 13 [Review]
-
(2008)
Mol Med Rep
, vol.1
, pp. 3-13
-
-
Perletti, G.1
Vral, A.2
Patrosso, M.C.3
Marras, E.4
Ceriani, I.5
Willems, P.6
-
11
-
-
33645346848
-
New findings relate aminoglycoside ototoxicity to cumulative plasma or perilymph AUC
-
A. Beaubien New findings relate aminoglycoside ototoxicity to cumulative plasma or perilymph AUC Infect Dis Newsl 1992 11
-
(1992)
Infect Dis Newsl
, pp. 11
-
-
Beaubien, A.1
-
12
-
-
0032814522
-
Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity
-
M.J. Rybak, B.J. Abate, S.L. Kang, M.J. Ruffing, S.A. Lerner, and G.L. Drusano Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity Antimicrob Agents Chemother 43 1999 1549 1555
-
(1999)
Antimicrob Agents Chemother
, vol.43
, pp. 1549-1555
-
-
Rybak, M.J.1
Abate, B.J.2
Kang, S.L.3
Ruffing, M.J.4
Lerner, S.A.5
Drusano, G.L.6
-
13
-
-
0025881811
-
Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration
-
A.R. Beaubien, E. Ormsby, A. Bayne, K. Carrier, G. Crossfield, M. Downes, and et al. Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration Antimicrob Agents Chemother 35 1991 1070 1074
-
(1991)
Antimicrob Agents Chemother
, vol.35
, pp. 1070-1074
-
-
Beaubien, A.R.1
Ormsby, E.2
Bayne, A.3
Carrier, K.4
Crossfield, G.5
Downes, M.6
-
14
-
-
84925643716
-
Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009
-
R. van Altena, G. de Vries, C.H. Haar, W.C. de Lange, C. Magis-Escurra, S. van den Hof, and et al. Highly successful treatment outcome of multidrug-resistant tuberculosis in The Netherlands, 2000-2009 Int J Tuberc Lung Dis 19 2015 406 412
-
(2015)
Int J Tuberc Lung Dis
, vol.19
, pp. 406-412
-
-
Van Altena, R.1
De Vries, G.2
Haar, C.H.3
De Lange, W.C.4
Magis-Escurra, C.5
Van Den Hof, S.6
-
15
-
-
84861043474
-
Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs
-
author reply 1766
-
J.W. Alffenaar Dried blood spot analysis combined with limited sampling models can advance therapeutic drug monitoring of tuberculosis drugs J Infect Dis 205 2012 1765 1766 [author reply 1766]
-
(2012)
J Infect Dis
, vol.205
, pp. 1765-1766
-
-
Alffenaar, J.W.1
-
16
-
-
84908152087
-
Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method
-
J.A. Dijkstra, M.G. Sturkenboom, K. Hateren, R.A. Koster, B. Greijdanus, and J.W. Alffenaar Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method Bioanalysis 6 2014 2125 2133
-
(2014)
Bioanalysis
, vol.6
, pp. 2125-2133
-
-
Dijkstra, J.A.1
Sturkenboom, M.G.2
Hateren, K.3
Koster, R.A.4
Greijdanus, B.5
Alffenaar, J.W.6
-
18
-
-
84873048566
-
Benchmarking therapeutic drug monitoring software: A review of available computer tools
-
A. Fuchs, C. Csajka, Y. Thoma, T. Buclin, and N. Widmer Benchmarking therapeutic drug monitoring software: a review of available computer tools Clin Pharmacokinet 52 2013 9 22
-
(2013)
Clin Pharmacokinet
, vol.52
, pp. 9-22
-
-
Fuchs, A.1
Csajka, C.2
Thoma, Y.3
Buclin, T.4
Widmer, N.5
-
19
-
-
0033841587
-
Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen
-
D. Xuan, J.F. Lu, D.P. Nicolau, and C.H. Nightingale Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen Int J Antimicrob Agents 15 2000 185 191
-
(2000)
Int J Antimicrob Agents
, vol.15
, pp. 185-191
-
-
Xuan, D.1
Lu, J.F.2
Nicolau, D.P.3
Nightingale, C.H.4
-
20
-
-
33845353064
-
Performance of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data sets
-
J.H. Proost, and D.J. Eleveld Performance of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data sets Pharm Res 23 2006 2748 2759
-
(2006)
Pharm Res
, vol.23
, pp. 2748-2759
-
-
Proost, J.H.1
Eleveld, D.J.2
-
21
-
-
75649136552
-
Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis
-
J.W. Alffenaar, J.G. Kosterink, R. van Altena, T.S. van der Werf, D.R. Uges, and J.H. Proost Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis Ther Drug Monit 32 2010 97 101
-
(2010)
Ther Drug Monit
, vol.32
, pp. 97-101
-
-
Alffenaar, J.W.1
Kosterink, J.G.2
Van Altena, R.3
Van Der Werf, T.S.4
Uges, D.R.5
Proost, J.H.6
-
22
-
-
80051783211
-
Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis
-
A.D. Pranger, J.G. Kosterink, R. van Altena, R.E. Aarnoutse, T.S. van der Werf, D.R. Uges, and et al. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis Ther Drug Monit 33 2011 350 354
-
(2011)
Ther Drug Monit
, vol.33
, pp. 350-354
-
-
Pranger, A.D.1
Kosterink, J.G.2
Van Altena, R.3
Aarnoutse, R.E.4
Van Der Werf, T.S.5
Uges, D.R.6
-
23
-
-
84870474781
-
Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies
-
Y. Wang, P.R. Jadhav, M. Lala, and J.V. Gobburu Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies J Clin Pharmacol 52 2012 1601 1606
-
(2012)
J Clin Pharmacol
, vol.52
, pp. 1601-1606
-
-
Wang, Y.1
Jadhav, P.R.2
Lala, M.3
Gobburu, J.V.4
-
24
-
-
0031955799
-
Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults
-
M. Tod, O. Lortholary, D. Seytre, R. Semaoun, B. Uzzan, L. Guillevin, and et al. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults Antimicrob Agents Chemother 42 1998 849 856
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 849-856
-
-
Tod, M.1
Lortholary, O.2
Seytre, D.3
Semaoun, R.4
Uzzan, B.5
Guillevin, L.6
-
25
-
-
79959733531
-
Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity
-
R. Galvez, C. Luengo, R. Cornejo, J. Kosche, C. Romero, E. Tobar, and et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity Int J Antimicrob Agents 38 2011 146 151
-
(2011)
Int J Antimicrob Agents
, vol.38
, pp. 146-151
-
-
Galvez, R.1
Luengo, C.2
Cornejo, R.3
Kosche, J.4
Romero, C.5
Tobar, E.6
-
26
-
-
0025355962
-
Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity
-
R. Garraffo, H.B. Drugeon, P. Dellamonica, E. Bernard, and P. Lapalus Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity Antimicrob Agents Chemother 34 1990 614 621
-
(1990)
Antimicrob Agents Chemother
, vol.34
, pp. 614-621
-
-
Garraffo, R.1
Drugeon, H.B.2
Dellamonica, P.3
Bernard, E.4
Lapalus, P.5
-
27
-
-
6944234949
-
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling
-
T. Gumbo, A. Louie, M.R. Deziel, L.M. Parsons, M. Salfinger, and G.L. Drusano Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling J Infect Dis 190 2004 1642 1651
-
(2004)
J Infect Dis
, vol.190
, pp. 1642-1651
-
-
Gumbo, T.1
Louie, A.2
Deziel, M.R.3
Parsons, L.M.4
Salfinger, M.5
Drusano, G.L.6
-
28
-
-
15944414245
-
Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia
-
M. Bernabeu-Wittel, C. Pichardo, A. García-Curiel, M.E. Pachón-Ibáñez, J. Ibáñez-Martínez, M.E. Jiménez-Mejías, and et al. Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia Clin Microbiol Infect 11 2005 319 325
-
(2005)
Clin Microbiol Infect
, vol.11
, pp. 319-325
-
-
Bernabeu-Wittel, M.1
Pichardo, C.2
García-Curiel, A.3
Pachón-Ibáñez, M.E.4
Ibáñez-Martínez, J.5
Jiménez-Mejías, M.E.6
-
29
-
-
2442708877
-
Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections
-
E. Nuermberger, and J. Grosset Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections Eur J Clin Microbiol Infect Dis 23 2004 243 255
-
(2004)
Eur J Clin Microbiol Infect Dis
, vol.23
, pp. 243-255
-
-
Nuermberger, E.1
Grosset, J.2
-
30
-
-
84902185616
-
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: A TBNET consensus statement
-
C. Lange, I. Abubakar, J.W. Alffenaar, G. Bothamley, J.A. Caminero, A.C. Carvalho, and et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement Eur Respir J 44 2014 23 63
-
(2014)
Eur Respir J
, vol.44
, pp. 23-63
-
-
Lange, C.1
Abubakar, I.2
Alffenaar, J.W.3
Bothamley, G.4
Caminero, J.A.5
Carvalho, A.C.6
-
31
-
-
84925234402
-
Therapeutic drug monitoring: How to improve drug dosage and patient safety in tuberculosis treatment
-
G. Sotgiu, J.W. Alffenaar, R. Centis, L. D'Ambrosio, A. Spanevello, A. Piana, and et al. Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment Int J Infect Dis 32 2015 101 104
-
(2015)
Int J Infect Dis
, vol.32
, pp. 101-104
-
-
Sotgiu, G.1
Alffenaar, J.W.2
Centis, R.3
D'Ambrosio, L.4
Spanevello, A.5
Piana, A.6
-
32
-
-
85027952108
-
Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin
-
C. Magis-Escurra, H.M. Later-Nijland, J.W. Alffenaar, J. Broeders, D.M. Burger, R. van Crevel, and et al. Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin Int J Antimicrob Agents 44 2014 229 234
-
(2014)
Int J Antimicrob Agents
, vol.44
, pp. 229-234
-
-
Magis-Escurra, C.1
Later-Nijland, H.M.2
Alffenaar, J.W.3
Broeders, J.4
Burger, D.M.5
Van Crevel, R.6
|